Literature DB >> 14711935

Cardiac ion channel effects of tolterodine.

Jiesheng Kang1, Xiao-Liang Chen, Hongge Wang, Junzhi Ji, William Reynolds, Sungtaek Lim, James Hendrix, David Rampe.   

Abstract

Tolterodine is a muscarinic antagonist widely used in the treatment of urinary incontinence. Although tolterodine has not been reported to alter cardiac repolarization, it is chemically related to other muscarinic antagonists known to prolong cardiac repolarization. For this reason, we studied the effects of tolterodine on cardiac ion channels and action potential recordings. Using patch-clamp electrophysiology, we found that tolterodine was a potent antagonist of the human ether-a-go-go-related gene (HERG) K(+) channel, displaying an IC(50) value of 17 nM. This potency was similar to that observed for the antiarrhythmic drug dofetilide (IC(50) of 11 nM). Tolterodine block of HERG displayed a positive voltage dependence, suggesting an interaction with an activated state. Tolterodine had little effect on the human cardiac Na(+) channel at concentrations of up to 1 microM. Inhibition of L-type Ca(2+) currents by tolterodine was frequency-dependent with IC(50) values measuring 143 and 1084 nM at 1 and 0.1 Hz, respectively. Both tolterodine and dofetilide prolonged action potential duration in single guinea pig myocytes over the concentration range of 3 to 100 nM. However, prolongation was significantly larger for dofetilide compared with tolterodine. Tolterodine seems to be an unusual drug in that it blocks HERG with high affinity, but produces little QT prolongation clinically. Low plasma levels after therapeutic doses combined with mixed ion channel effects, most notably Ca(2+) channel blockade, may serve to attenuate the QT prolonging effects of this potent HERG channel antagonist.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14711935     DOI: 10.1124/jpet.103.062182

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

1.  Role of mixed ion channel effects in the cardiovascular safety assessment of the novel anti-MRSA fluoroquinolone JNJ-Q2.

Authors:  G Eichenbaum; M K Pugsley; D J Gallacher; R Towart; G McIntyre; U Shukla; J M Davenport; H R Lu; J Rohrbacher; V Hillsamer
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

2.  L-type Ca2+ channel responses to bay k 8644 in stem cell-derived cardiomyocytes are unusually dependent on holding potential and charge carrier.

Authors:  Junzhi Ji; Jiesheng Kang; David Rampe
Journal:  Assay Drug Dev Technol       Date:  2014-08       Impact factor: 1.738

3.  Effects of antipsychotic drugs on I(to), I (Na), I (sus), I (K1), and hERG: QT prolongation, structure activity relationship, and network analysis.

Authors:  William J Crumb; Sean Ekins; R Dustan Sarazan; James H Wikel; Steven A Wrighton; Christopher Carlson; Charles M Beasley
Journal:  Pharm Res       Date:  2006-05-25       Impact factor: 4.200

Review 4.  Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction.

Authors:  Karl-Erik Andersson; Lysanne Campeau; Brian Olshansky
Journal:  Br J Clin Pharmacol       Date:  2011-08       Impact factor: 4.335

5.  Tolterodine reduces veratridine-augmented late INa, reverse-INCX and early afterdepolarizations in isolated rabbit ventricular myocytes.

Authors:  Chao Wang; Lei-Lei Wang; Chi Zhang; Zhen-Zhen Cao; An-Tao Luo; Pei-Hua Zhang; Xin-Rong Fan; Ji-Hua Ma
Journal:  Acta Pharmacol Sin       Date:  2016-08-29       Impact factor: 6.150

6.  Electrophysiological profile of propiverine--relationship to cardiac risk.

Authors:  Torsten Christ; Erich Wettwer; Melinda Wuest; Manfred Braeter; Frank Donath; Pascal Champeroux; Serge Richard; Ursula Ravens
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-12-19       Impact factor: 3.000

Review 7.  The Q-T interval and antimuscarinic drugs.

Authors:  Roger Dmochowski; David R Staskin
Journal:  Curr Urol Rep       Date:  2005-11       Impact factor: 2.862

8.  Evidence of more ion channels inhibited by celecoxib: KV1.3 and L-type Ca(2+) channels.

Authors:  Roman V Frolov; Satpal Singh
Journal:  BMC Res Notes       Date:  2015-03-01

9.  Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines.

Authors:  H R Lu; E Vlaminckx; A N Hermans; J Rohrbacher; K Van Ammel; R Towart; M Pugsley; D J Gallacher
Journal:  Br J Pharmacol       Date:  2008-05-19       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.